1. Janssen’s Tremfya (guselkumab) Receives the US FDA’s Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis Published: Sept 10, 2020 | Tags: Janssen, Tremfya, Guselkumab, Biologic, US FDA, Selective, IL-23 inhibitor, Active Psoriatic Arthritis, Severe Plaque Psoriasis, human mAb 2. Janssen Reports sBLA Submission to the US FDA for Darzalex Faspro (daratumumab […]Read More
Shots: Redx is working on study including lower starting dose and enhanced safety monitoring, assessing safety and tolerability of drug in patients with advance malignancies Redx claims that RXC004 a porcupine inhibitor belong to WNT signalling pathway, seems to be an attractive combination companion for immune-oncology agents Redx will finalize the suspended protocol for dosing […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
